DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Positive impactCompany

Sai Parenterals’ Australian arm, Noumed Pharmaceuticals, inks ₹1300 cr OTC supply pact

BusinessLine 1 Jul·1 Jul 2026, 2:12 pm

The exclusive OTC medicine supply agreement is for a period of 7.5 years with a further option of 3 years extension

Stocks in this story

SAI Parenterals₹588.35▼ 3.88%

Key takeaways

Concerns SAI Parenterals (SAIPARENT).
Category: Company.
AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for SAI Parenterals. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at BusinessLine.